Nymox Announces $5 Million Registered Direct Offering
March 18 2022 - 8:30AM
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced it
has entered into definitive agreements with institutional and
accredited investors for the purchase and sale of 3,030,304 common
shares at a purchase price of $1.65 per share in a registered
direct offering for gross proceeds of approximately $5 million
before deducting placement agent fees and expenses. The Company has
also agreed to issue to the investors, in a concurrent private
placement, unregistered warrants to purchase up to an aggregate of
3,030,304 common shares. The warrants are exercisable immediately
at an exercise price of $2.00 per share and will expire five (5)
years from the date of an effective registration statement covering
the shares underlying the warrants. The closing of the offering is
expected to occur on or about March 22, 2022, subject to the
satisfaction of customary closing conditions.
Nymox intends to use the proceeds for general
corporate purposes, including working capital.
A.G.P./Alliance Global Partners is acting as
sole placement agent for the offering. This offering of
the common shares (but not the warrants or the common shares
underlying the warrants) is being made pursuant to an effective
shelf registration statement on Form F-3 (File No. 333-261571)
previously filed with the U.S. Securities and Exchange Commission
(the “SEC”). A prospectus supplement describing the terms of the
proposed offering will be filed with the SEC and will be available
on the SEC’s website located at http://www.sec.gov. Electronic
copies of the prospectus supplement may be obtained, when
available, from A.G.P./Alliance Global Partners, 590 Madison
Avenue, 28th Floor, New York, NY 10022, or by telephone at (212)
624-2060, or by email at prospectus@allianceg.com. Interested
parties should read in their entirety the prospectus supplement and
the accompanying prospectus and the other documents that Nymox has
filed with the SEC that are incorporated by reference in such
prospectus supplement and the accompanying prospectus, which
provide more information about Nymox and such offering.
The warrants described above were offered in a
private placement under Section 4(a)(2) of the Securities Act of
1933, as amended (the “Act”), and Regulation D promulgated
thereunder and, along with the common shares underlying the
warrants, have not been registered under the Act, or applicable
state securities laws. Accordingly, the warrants and the underlying
common shares may not be offered or sold in the United States
except pursuant to an effective registration statement or an
applicable exemption from the registration requirements of the Act
and such applicable state securities laws.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy nor shall there be
any sale of these securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Nymox Pharmaceutical Corporation
Nymox Pharmaceutical Corporation specializes in
the research and development of therapeutics and diagnostics, with
a particular emphasis on products targeted for the unmet needs of
the rapidly aging male population in developed economies. The
Company’s lead drug candidate for benign prostatic hyperplasia
(BPH), Fexapotide Triflutate (FT) was submitted in a New Drug
Application (NDA) to the FDA on March 3, 2022. The Company will
soon be submitting applications in other major jurisdictions,
including Europe.
For more information please contact info@nymox.com or
800-936-9669.
Forward-Looking Statements
To the extent that statements contained in this
press release are not descriptions of historical facts regarding
Nymox, they are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995, including statements regarding use of proceeds for the
offering, the closing of the offering, the need for new options to
treat BPH and prostate cancer, the potential of Fexapotide to treat
BPH and prostate cancer and the estimated timing of further
developments for Fexapotide.
Such forward-looking statements involve
substantial risks and uncertainties that could cause our clinical
development program, future results, performance or achievements to
differ significantly from those expressed or implied by the
forward-looking statements.
Such risks and uncertainties include, among
others, the uncertainties inherent in the clinical drug development
process, including the regulatory approval process, the timing of
Nymox's regulatory filings, Nymox's substantial dependence on
Fexapotide, Nymox's commercialization plans and efforts and other
matters that could affect the availability or commercial potential
of Fexapotide. Nymox undertakes no obligation to update or revise
any forward looking statements. For a further description of the
risks and uncertainties that could cause actual results to differ
from those expressed in these forward-looking statements, as well
as risks relating to the business of Nymox in general, see Nymox's
current and future reports filed with the U.S. Securities and
Exchange Commission. The information contained in this press
release is as of the date of the press release and Nymox assumes no
duty to update such information.
For Further Information
Contact:
Randall LanhamNymox Pharmaceutical
Corporation1-800-93NYMOXwww.nymox.cominfo@nymox.com
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Apr 2023 to Apr 2024